Glicoast-M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The combination therapy offers complementary mechanisms of action, facilitating better blood glucose regulation in patients inadequately controlled by diet and exercise alone or monotherapy. Glicoast-M 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. It is essential to monitor blood glucose levels regularly to adjust dosage appropriately and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. This medication should be used under medical supervision with periodic assessment of renal function and glycemic parameters to ensure safety and efficacy.